

 Early Warning System

EBRD-55995

DFF - Project Celon



Quick Facts

Countries	Slovakia
Specific Location	Zilina region
Financial Institutions	European Bank for Reconstruction and Development (EBRD)
Status	Approved
Bank Risk Rating	B
Voting Date	2025-07-22
Borrower	Celon Pharma Slovakia s. r. o.
Sectors	Industry and Trade
Investment Type(s)	Loan
Investment Amount (USD)	\$ 27.00 million
Project Cost (USD)	\$ 41.08 million



Project Description

According to the Bank's website, the project consists of a senior secured loan in the amount of up to EUR23 million for the construction works within an existing, leased production facility, as well as equipment and commencing the plant operations. The facility will be located in Zilina region, Slovakia, and used for the production of the semaglutide-based diabetes type II medicine.



Early Warning System Project Analysis

Categorised B (ESP 2019). Environmental and social risks associated with expansion of the Celon Pharma's production into Slovakia via establishing a new Zilina facility, focused on the R&D and production of medicines utilizing pen injector technology, are site-specific and can be readily mitigated.



Investment Description

- European Bank for Reconstruction and Development (EBRD)

a senior secured loan in the amount of up to EUR23 million



Private Actors Description

Celon Pharma Slovakia s. r. o. was established in October 2024 for the purpose of production of a semaglutide-based drug used primarily for the treatment of diabetes type II and secondarily in weight loss.

Celon Pharma S.A. (the "Group") is a Polish pharmaceutical company operating in the field of generic drugs manufacturing as well as R&D in the area of complex generic/biological drugs. The Group has its own production facility in central Poland together with an R&D centre.



Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	Celon Pharma Slovakia s. r. o.	Client	-



Contact Information

Malgorzata Siewierska
info@celonpharma.com
<https://celonpharma.com/en/>

ACCESS TO INFORMATION

You can request information by emailing: accessinfo@ebrd.com or by using this electronic form:
<https://www.ebrd.com/eform/information-request>

ACCOUNTABILITY MECHANISM OF EBRD

The Project Complaint Mechanism (PCM) is the independent complaint mechanism and fact-finding body for people who have been or are likely to be adversely affected by an European Bank for Reconstruction and Development (EBRD)-financed project. If you submit a complaint to the PCM, it may assess compliance with EBRD's own policies and procedures to prevent harm to the environment or communities or it may assist you in resolving the problem that led to the complaint through a dialogue with those implementing the project. Additionally, the PCM has the authority to recommend a project be suspended in the event that harm is imminent.

You can contact the PCM at: pcm@ebrd.com or you can submit a complaint online using an online form at:
http://www.ebrd.com/eform/pcm/complaint_form?language=en

You can learn more about the PCM and how to file a complaint at: <http://www.ebrd.com/work-with-us/project-finance/project-complaint-mechanism.html>